Table of contents:
Video: WHO Again Halts Studies Of Hydroxychloroquine For COVID-19
WHO again halts studies of hydroxychloroquine for COVID-19
The organization believes that the accumulated data indicate the ineffectiveness of the drug for this infection.
Photo: Christopher Occhicone / Bloomberg
For the second time within a month, the World Health Organization decided to stop clinical trials of hydroxychloroquine in COVID-19. This decision was based on an analysis of the latest evidence and WHO's own preliminary data. The latter indicate that the drug does not help with this disease.
WHO announced the start of a major study (SOLIDARITY) on a range of COVID-19 drugs, including hydroxychloroquine, in March. In late May, a major paper published in The Lancet said the drug was not showing any efficacy. This study was later withdrawn, but the WHO managed to suspend the study of chloroquine and hydroxychloroquine.
The new halt in hydroxychloroquine research was announced by WHO expert Ana Maria Genao-Restrepo at a regular briefing on 17 June. She stated that the most important reasons for this were the RECOVERY, SOLIDARITY, and Cochrane Fellowship data. The SOLIDARITY study for other drugs is ongoing.
Popular by topic
Scientists suggest older people may need additional vaccinations
The vaccine successfully stimulated the production of antibodies and T cells, the scientists did not find any serious side effects
Such a rash on the mucous membrane is characteristic of viral infections
Scientists have made such predictions based on a detailed analysis of the spread of coronavirus in Wuhan
E-cigarettes can cause a condition similar to COVID-19 - rehab. Find out the details on the Medportal website